SYBX vs. PPBT, GNLX, ACRS, BNTC, LABP, PYRGF, ALRN, MNOV, ANVS, and BTAI
Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Purple Biotech (PPBT), Genelux (GNLX), Aclaris Therapeutics (ACRS), Benitec Biopharma (BNTC), Landos Biopharma (LABP), PyroGenesis Canada (PYRGF), Aileron Therapeutics (ALRN), MediciNova (MNOV), Annovis Bio (ANVS), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical preparations" industry.
Purple Biotech (NASDAQ:PPBT) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations.
Synlogic received 318 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 92.86% of users gave Purple Biotech an outperform vote while only 69.54% of users gave Synlogic an outperform vote.
Purple Biotech currently has a consensus target price of $9.00, indicating a potential upside of 1,014.55%. Synlogic has a consensus target price of $65.00, indicating a potential upside of 4,066.67%. Given Purple Biotech's higher possible upside, analysts plainly believe Synlogic is more favorable than Purple Biotech.
9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 8.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Purple Biotech has higher earnings, but lower revenue than Synlogic. Purple Biotech is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.
Purple Biotech has a net margin of 0.00% compared to Purple Biotech's net margin of -2,284.65%. Synlogic's return on equity of -62.26% beat Purple Biotech's return on equity.
In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. Purple Biotech's average media sentiment score of 1.44 beat Synlogic's score of 0.11 indicating that Synlogic is being referred to more favorably in the news media.
Purple Biotech has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Summary
Purple Biotech and Synlogic tied by winning 8 of the 16 factors compared between the two stocks.
Get Synlogic News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synlogic Competitors List
Related Companies and Tools
